Understanding how Pseudomonas aeruginosa becomes resistant to cefiderocol.
Emergence of TonB-dependent receptor mediated cefiderocol resistance among multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates.
This study is looking into how certain tough bacteria, called multidrug-resistant Pseudomonas aeruginosa, become resistant to a new antibiotic called cefiderocol, which could help doctors better treat patients with infections caused by these bacteria.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10766821 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the resistance of multidrug-resistant Pseudomonas aeruginosa to cefiderocol, a novel antibiotic. By analyzing the genetic changes in clinical isolates, the study aims to identify how these bacteria lose the ability to take up the drug effectively. The approach includes examining the outer membrane proteins responsible for drug transport and assessing the impact of specific mutations on antibiotic efficacy. Patients with infections caused by these resistant strains may benefit from insights gained through this research.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research are patients with infections caused by multidrug-resistant Pseudomonas aeruginosa, particularly those in intensive care settings.
Not a fit: Patients with infections caused by non-resistant strains of Pseudomonas aeruginosa may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for infections caused by multidrug-resistant Pseudomonas aeruginosa.
How similar studies have performed: Previous research has shown success in understanding antibiotic resistance mechanisms in other pathogens, suggesting that this approach may yield valuable insights.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Miller, William R — Methodist Hospital Research Institute
- Study coordinator: Miller, William R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.